Literature DB >> 21442260

PET/CT for staging lung cancer: costly or cost-saving?

Andreas K Buck, Ken Herrmann, Jonas Schreyögg.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21442260     DOI： 10.1007/s00259-011-1803-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  13 in total

Review 1.  Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches.

Authors:  Andreas K Buck; Ken Herrmann; Tom Stargardt; Tobias Dechow; Bernd Joachim Krause; Jonas Schreyögg
Journal:  J Nucl Med       Date:  2010-02-11       Impact factor: 10.057

2.  Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer.

Authors:  Jonas Schreyögg; Julia Weller; Tom Stargardt; Ken Herrmann; Christina Bluemel; Tobias Dechow; Gerhard Glatting; Bernd J Krause; Felix Mottaghy; Sven N Reske; Andreas K Buck
Journal:  J Nucl Med       Date:  2010-11       Impact factor: 10.057

3.  Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.

Authors:  Sung Shine Shim; Kyung Soo Lee; Byung-Tae Kim; Myung Jin Chung; Eun Jung Lee; Joungho Han; Joon Young Choi; O Jung Kwon; Young Mog Shim; Seonwoo Kim
Journal:  Radiology       Date:  2005-07-12       Impact factor: 11.105

4.  Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006.

Authors:  Michaela A Dinan; Lesley H Curtis; Bradley G Hammill; Edward F Patz; Amy P Abernethy; Alisa M Shea; Kevin A Schulman
Journal:  JAMA       Date:  2010-04-28       Impact factor: 56.272

5.  Preoperative staging of non-small-cell lung cancer with positron-emission tomography.

Authors:  R M Pieterman; J W van Putten; J J Meuzelaar; E L Mooyaart; W Vaalburg; G H Koëter; V Fidler; J Pruim; H J Groen
Journal:  N Engl J Med       Date:  2000-07-27       Impact factor: 91.245

6.  Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial.

Authors:  Harm van Tinteren; Otto S Hoekstra; Egbert F Smit; Jan H A M van den Bergh; Ad J M Schreurs; Roland A L M Stallaert; Piet C M van Velthoven; Emile F I Comans; Fred W Diepenhorst; Paul Verboom; Johan C van Mourik; Pieter E Postmus; Maarten Boers; Gerrit J J Teule
Journal:  Lancet       Date:  2002-04-20       Impact factor: 79.321

7.  Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).

Authors:  Frank C Detterbeck; Michael A Jantz; Michael Wallace; Johan Vansteenkiste; Gerard A Silvestri
Journal:  Chest       Date:  2007-09       Impact factor: 9.410

8.  Preoperative staging of lung cancer with combined PET-CT.

Authors:  Barbara Fischer; Ulrik Lassen; Jann Mortensen; Søren Larsen; Annika Loft; Anne Bertelsen; Jesper Ravn; Paul Clementsen; Asbjørn Høgholm; Klaus Larsen; Torben Rasmussen; Susanne Keiding; Asger Dirksen; Oke Gerke; Birgit Skov; Ida Steffensen; Hanne Hansen; Peter Vilmann; Grete Jacobsen; Vibeke Backer; Niels Maltbaek; Jesper Pedersen; Henrik Madsen; Henrik Nielsen; Liselotte Højgaard
Journal:  N Engl J Med       Date:  2009-07-02       Impact factor: 91.245

9.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.

Authors:  Didier Lardinois; Walter Weder; Thomas F Hany; Ehab M Kamel; Stephan Korom; Burkhardt Seifert; Gustav K von Schulthess; Hans C Steinert
Journal:  N Engl J Med       Date:  2003-06-19       Impact factor: 91.245

10.  Multi-modality mediastinal staging for lung cancer among medicare beneficiaries.

Authors:  Farhood Farjah; David R Flum; Scott D Ramsey; Patrick J Heagerty; Rebecca Gaston Symons; Douglas E Wood
Journal:  J Thorac Oncol       Date:  2009-03       Impact factor: 15.609
View more
  8 in total

1.  PET-CT in the staging and treatment of non-small-cell lung cancer.

Authors:  Patricia Ibeas; Blanca Cantos; José Manuel Gasent; Begoña Rodríguez; Mariano Provencio
Journal:  Clin Transl Oncol       Date:  2011-06       Impact factor: 3.405

2.  Added value of cost-utility analysis in simple diagnostic studies of accuracy: (18)F-fluoromethylcholine PET/CT in prostate cancer staging.

Authors:  Oke Gerke; Mads H Poulsen; Poul Flemming Høilund-Carlsen
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

3.  Measurement of primary tumor volume by PET-CT to evaluate risk of mediastinal nodal involvement in NSCLC patients with clinically negative N2 lymph nodes.

Authors:  Andrzej Lebioda; Roman Makarewicz; Bogdan Małkowski; Maciej Dancewicz; Janusz Kowalewski; Wieslawa Windorbska
Journal:  Rep Pract Oncol Radiother       Date:  2013-01-05

4.  Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer.

Authors:  Satoshi Takeuchi; Benjapa Khiewvan; Patricia S Fox; Stephen G Swisher; Eric M Rohren; Roland L Bassett; Homer A Macapinlac
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01-18       Impact factor: 9.236

Review 5.  Prospective of ⁶⁸Ga-radiopharmaceutical development.

Authors:  Irina Velikyan
Journal:  Theranostics       Date:  2013-12-10       Impact factor: 11.556

Review 6.  Positron emission tomography-computed tomography in the management of lung cancer: An update.

Authors:  Punit Sharma; Harmandeep Singh; Sandip Basu; Rakesh Kumar
Journal:  South Asian J Cancer       Date:  2013-07

7.  Spiking Cortical Model Based Multimodal Medical Image Fusion by Combining Entropy Information with Weber Local Descriptor.

Authors:  Xuming Zhang; Jinxia Ren; Zhiwen Huang; Fei Zhu
Journal:  Sensors (Basel)       Date:  2016-09-15       Impact factor: 3.576

Review 8.  PET/CT in the staging of the non-small-cell lung cancer.

Authors:  Fangfang Chao; Hong Zhang
Journal:  J Biomed Biotechnol       Date:  2012-03-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.